We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2019 to Apr 2024
By Cecilia Butini
Sanofi SA said Monday that it has entered into an agreement to acquire U.K.-based biopharmaceutical company Kymab for an upfront payment of about $1.1 billion.
The French pharmaceutical major said the deal also includes the payment of up to $350 million upon achievement of certain milestones.
The acquisition of Kymab--which focuses on the development of fully human monoclonal antibodies--would give Sanofi full global rights to the KY1005 monoclonal antibody, it said. The antibody can be used in the treatment of a range of immune and inflammatory diseases, according to Sanofi.
The acquisition will be financed in cash and is expected to close in the first half of 2021, the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 11, 2021 03:05 ET (08:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
